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This dissertation elaborates on two aspects that characterise the early stages of the 
innovation process in biotechnology: the financing of basic knowledge and the 
appropriation of value for commercial purposes. 
The rise of biotechnology industry and the expanding role of academia in the market 
arena, have brought important changes to the division of innovative labour between 
public and private actors. Prior research of knowledge transfer has focused primarily 
on academic entrepreneurship and a large pressure has been placed on universities to 
commercialise research discoveries. This dissertation takes a different look at the way 
the innovation process unfolds, focusing on the scientific founders of European 
biotechnology companies that originate new drugs and tracing back the scientific 
pathways that characterise the transformation of ‘R’ into ‘D’. 
Consisting of three published essays, this doctoral work brings together the literature 
on knowledge transfer, scientific human capital and scientific entrepreneurship. It 
starts with a systematic revision of the literature, exploring the mechanisms of 
knowledge transfer between academia and industry. On the identified transport 
mechanisms, it frames a new taxonomy which defines ‘channels’ and ‘processes’ of 
knowledge transfer based on levels of individual involvement. Furthermore, starting 
from publications, patents and IPO documents by biotech founders, a bibliometric 
analysis and regression model are developed to identify the scientific origins of 
biopharmaceutical discoveries and the extents by which these are appropriated for 
economic use. 
The essays of this thesis show that the knowledge base upon which biotechnology 
start-ups are established is created by actors with heterogeneous scientific and career 
backgrounds across academia and industry. Public institutions back up the creation of 
valuable inventions by financing most of the basic research conducted by scientists 
before they start their own biotech start-ups. Furthermore, work experience at 
university increases the chances that biotech companies appropriate the intellectual 
property rights of academic inventions. In contrast, spending their careers in the 
private sector brings scientists to disclose their inventions to their private employers. 
As a result, these findings contribute to understanding the dynamics behind the private 
ownership landscape of academic patents in Europe. 
In conclusion, through an innovative methodology centred on the scientific founders 
of biotech start-ups, this thesis provides new evidence to understand the critical roles 
that public and private organisations play at the early stage of the innovation process. 
This research has the potential to inform the debate on whether and how risks and 
rewards of investments in innovation can be aligned with contributors to the 
innovation process.  
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The appropriation of knowledge and its valorisation has become a key characteristic 
of the modern pharmaceutical and biotechnology industries. Since the advent of the 
biomedical era, many compounds travel through both public and private sectors while 
changing hands multiple times (Pisano, 2006). Innovation hinges on the coordinated 
efforts of governments, universities, biotechnology and established life sciences firms 
involved in multi-lateral interactions and overlapping networks. The convergence on 
shared means relies, on the one side, on the shift from the traditional mission of 
educating students which universities have broadened to include the patenting and 
commercialisation of research discoveries; and on the other side, on the transformation 
of knowledge into commodities as the core of the biotechnology sector (Bok, 2009; 
Cohen, Nelson and Walsh, 2002; Perkmann et al., 2013; D’Este and Patel, 2007; Wang 
et al., 2015; Etzkowitz and Leydesdorff, 2000). Biotechnology firms, by capitalising 
on their networks in the academic community, play the role of assisting the 
development and the transfer of university-originated science to firms with in-house 
commercialisation capabilities (Stuart, Ozdemir and Ding, 2007). Pharma companies, 
in addition to the still-important in-house knowledge generation, observe this 
technological development on a global scale and acquire promising substances and 
technologies from smaller biotech companies or from academic research institutes so 
as to minimise their own risk  (Zeller, 2003). 
Despite theoretical discussions about ‘open’ innovation and innovation ‘eco-systems’ 
placing an emphasis upon the collective character of the innovation process, the 
fundamental fact that innovation is inherently an uncertain, cumulative and collective 
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process that unfolds over a long time makes it very difficult to track the genesis and 
the development of an idea into a marketed product. Even more challenging is the 
estimation of the risks and expected financial returns. In the dominant view, a key 
assumption is that fundamental knowledge is often created by publicly funded 
research and then acquired by companies through securing the ownership of 
intellectual property rights  (Zeller, 2007; Angell, 2005). This role is usually played 
by biotechnology companies that position themselves between a) the organisations 
embarking on the risks of investments in knowledge creation, and b) the 
pharmaceutical companies selecting and developing the most promising candidates 
into viable commercial products (Powell, 1998). 
In the last decade, highly priced medicines and budgetary constraints from public 
health payers have raised questions such as whether the risks of value creation and the 
benefits from value extraction are fairly distributed among players in the innovation 
field  (Lazonick and Mazzucato, 2013). Traditionally, the economic answers around 
drug pricing and innovation were centred on two main assumptions (Roy, 2017), the 
primary discourse being that prices are justified based on the cost of drug research and 
development (DiMasi, Grabowski and Hansen, 2016). Under this logic, monopoly 
pricing is necessary to pay for the lengthy and failure-ridden process of successfully 
bringing a new therapy to market. This position has been backed up mostly by the 
work of the ‘Tufts Center for Drug and Development’, which has produced periodic 
estimations of the costs of research and development, arriving at a figure of US2.6$ 
billion per newly approved molecule in 2015 (DiMasi, Grabowski and Hansen, 2016). 
A second narrative that gained consensus among scholars and actors in the 
pharmaceutical industry, is centred around the so-called value-based pricing strategy. 
Within this view, higher prices reflect improved patient health outcomes and adverted 
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medical expenses, and therefore the definition of what constitutes value is based on 
cost-benefit research in health economics (Gregson et al., 2005). The benefits of new 
interventions involve measurement against a standard of care and a certain 
‘willingness to pay’ which is a monetary threshold set by public health systems.  
In recent times, both positions have been criticised on methodological standpoints, 
omissions and budgetary concerns (Reinhardt, 2015). For example, some authors have 
shown that the total marketing expenditure by pharma companies was higher than that 
incurred for research and development (Gagnon and Lexchin, 2008; Swanson, 2015). 
Also, scepticism has been shown towards the methodological challenge of measuring 
health outcomes in monetary terms  (Knapp and Mangalore, 2007; Nord, Daniels and 
Kamlet, 2009), and furthermore, the assumption that single patients are willing to pay 
more for better health outcomes places the responsibility of valuing innovative 
medicines on the ultimate buyer: the public health systems. 
Overall, it seems that the structural characteristics of production have been 
overshadowed in both the current theoretical and empirical debates on innovation. In 
fact, a separation has occurred at an academic level, with industrial economists 
focusing on market dynamics, such as whether a productivity crisis follows a decrease 
in the numbers of newly approved drugs, and health economists paying more attention 
to the estimation of health statuses and prices via health technology assessment 
analyses. Therefore, the nexus between value creation and value extraction has been 
partially left uncovered and the debate has remained somewhat silent on questions of 
who bears the risks of knowledge creation behind the development of new drugs, as 




As we will discuss in our theoretical chapter, this phenomenon has been largely 
studied by the literature on knowledge and technology transfer. In this context, the 
economic studies of science have mostly followed the trajectories of academics 
involved in commercialisation activities and university links with the industry. Much 
attention has been given to the analysis of academic spin-offs and academic patenting. 
Rather than attend to university-industry relations from the perspective of academic 
entrepreneurs and university spin-offs, this dissertation takes a different vantage point. 
It centres on the scientific founders of the biotechnology companies that originate new 
drugs, and tracks back the origins of the knowledge that leads to innovation. 
Furthermore, this work takes an innovative approach to the underlying phenomena by 
employing bibliometric and documentary data. 
Previous analyses have centred on the notion that the monetised transfer of knowledge 
and technologies is to a large extent based on intellectual property rights  (Zeller, 
2007). In fact, intellectual property titles are used to enable firms in knowledge-based 
industries to limit the uncontrolled diffusion of their products and to artificially create 
scarcity so to legitimise the exclusion of other companies from the use of knowledge  
(May, 1998; Sell and May, 2001). Furthermore, through the assignation of intellectual 
property rights, biotech start-ups acquire the inventions generated earlier by their 
research teams. Therefore, being that most of the biotech firms have no product at the 
time of founding and are often started by university scientists, publications as well as 
patents have become a valid bibliometric indicator of the usefulness and transferability 
of research outputs  (Lissoni, 2012; Meyer, 2000). Moreover, some empirical studies 
on scientific human capital have demonstrated the varying performance impact of a 
mix of scientists in terms of their orientation towards publishing and patenting (Dietz 
and Bozeman, 2005; Bozeman and Corley, 2004). For example, the importance of star 
5 
 
scientists, who show above average scientific performance and individual-level 
capabilities which become important extensions of the firm-level dynamic capabilities  
(Zucker and Darby, 2006b; Zucker and Darby, 1998). 
Yet, despite the potential for employing bibliometric sources of data, the existing body 
of literature has rarely led to these being incorporated into the structural analysis of 
the innovation process. Furthermore, few attempts have been made to consider 
heterogeneity among scientists who contribute to the creation of biotechnology 
enterprises and to investigate how this heterogeneity affects firms’ creation and 
appropriation strategies. 
Main scope and contribution 
The main argument of this dissertation is presented by unfolding the key elements in 
the economics of health, innovation and entrepreneurship, and overall to build an 
account of the relationship between science and technology. The intention here is to 
provide a logical flow and coherent overall story of how knowledge transforms into 
value and is directed for economic use. The empirical corpus of this thesis aims to 
respond to two specific research questions: What is the financial contribution to the 
knowledge which leads to the development of new pharmaceuticals? How is 
knowledge transferred and value appropriated? 
The dissertation focuses on some distinct aspects of the early stages of innovation 
which reflect in those employed in the three papers composing this work. The aim was 
to maintain a set of original objectives in each paper so that the papers would relate 
but not overlap. However, although the three essays represent an integrated and 
coherent whole, a few repetitions are unavoidable, as the same themes and ideas are 
developed and considered from different perspectives. 
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In first instance (Essay One), I reduce the ambiguity of university-industry relations 
by investigating the extant literature on the mechanisms of knowledge transfer. The 
results of this work define a gap in the literature, based on which I frame a new 
taxonomy centred on the concept of individual involvement and give direction to 
future research. 
The second empirical paper (Essay Two) explores the process of knowledge creation 
through the publications authored by scientists involved in the foundation of biotech 
start-ups in the United Kingdom. The analysis takes advantage of the information 
contained in the acknowledgment section of the publications made by the scientific 
founders so as to highlight the financial contribution given to the science behind the 
origination of new companies which originate drugs. 
Lastly, the third empirical paper (Essay Three) investigates how knowledge is 
appropriated for economic use. Here, the scientific human capital of European biotech 
founders is analysed based on the biographical information contained in IPO 
prospectuses. Research and career trajectories are then integrated into a regression 
model to estimate how they affect the assignation of intellectual property rights. 
This work provides evidence of the fundamental role played by public institutions 
financing the early and riskiest stages of innovation. I highlight that the value 
associated with early-stage invention is appropriated by the private sector through the 
assignation of intellectual property rights. Moreover, I show the incentives for 
scientists to assign property titles to the companies they help start, as a conduit to 
capitalise on their previous research and discoveries. 
Overall, the findings of this doctoral thesis can be used to map out a range of solutions 
that might be necessary to bring about change in the way that early innovation is 
7 
 
financed and the access to new interventions is provided. My hope is that by raising 
this set of enquiries, through this dissertation I can contribute to the larger effort 
already underway in moving biomedical innovation closer to human needs. 
Thesis outline 
This dissertation unfolds in four chapters. The first chapter details the theoretical 
landscape. Here, the focus is on building an analytical toolkit from the economics of 
innovation, entrepreneurship and health that accompany me in my investigation. This 
chapter illustrates and links the different theoretical lenses used in the three essays. 
The second chapter defines the rationales specific to each of the essays. Research 
questions and objectives are also stated and justified. In Chapter 3, I present the 
philosophical assumptions and map out the research strategy and methodology. 
Chapter 4 outline the main contributions by the three essays. The chapter includes a 
documentation of the contributions and limitations of the study, as well as potential 
research projects that my findings may provoke and reflections at policy level. 
Part II of this thesis contains the essays written in the form of scientific publications. 
The published versions of the first two works are reported, whereas the last paper is 
presented in the form by which to has been accepted for peer review and currently is 







CHAPTER 1: Theory 
 
According to definition by  Kerlinger (1966), theory is "a set of interrelated constructs, 
definitions and propositions that presents a systematic view of phenomena by 
specifying relations among variables, with a purpose of explaining and predicting 
phenomena". 
This chapter presents and discusses the main changes in the innovation landscape and 
theories linking the contributions by the three essays composing this thesis. The focus 
is on the role that scientific entrepreneurship plays as a conduit for the transfer of 
knowledge from non-economic to economic domains. To this end, I take a systemic 
approach to the orchestration of different theories in the economics of knowledge, 
innovation and entrepreneurship. 
 
Institutional Background 
The emergence of biotechnology marked a fundamental change in the way in which 
science moves from the laboratory to the market and it represents a prototypical 
example of the changing patterns of specialisation in inventive activity. 
Biotechnology has a ‘science-push’ origin which dates back to the pioneering work of 
Watson and Crick, who discovered the structure of DNA as a double helix in the early 
1950s (Watson and Crick, 1953). However, it was the development of recombinant 
DNA techniques by Herbert Boyer at UCSF and Stanley Cohen at Stanford in 1972, 
and the subsequent foundation of Genentech in 1976 to exploit these techniques which 
heralded the dawn of a new industry (Wakeman, 2008). Since then, the division of 
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innovative labour within the pharmaceutical industry has experienced profound 
modifications driven by both institutional and technical changes. 
Earlier in the 1960s and 1970s, the industry had been characterised by distinctive roles 
played by upstream not-for-profit organizations specialised in curiosity-driven basic 
research and downstream, for-profit companies involved in applied research 
(Cockburn, Iain, 2005). Upstream organisations usually took the form of taxpayer-
supported government labs, universities, research institutes and teaching hospitals. 
Not-for-profit researchers concentrated largely on fundamental science and were 
driven by extensive publication activity and peer-reviewed competition in order to 
establish priority and reputation, as well as the securing of grants required to fund their 
research (Whitley, 2000). Downstream pharmaceutical firms were mature 
organisations, originated within the 19th-century chemical industry. These firms were 
characterised by strong in-house capabilities ranging from drug discovery, through 
clinical development and regulatory affairs, to manufacturing and marketing  
(Cockburn, Iain M., 2004). 
Despite this vertical structure, many drug companies invested significant resources in 
‘blue sky’ basic research, and many academic researchers had close financial and 
contractual links with drug producers either through individual consulting 
arrangements or institutional research grants and partnership. Despite these caveats, 
the industry was still characterized by a clear distinction between upstream open 
science conducted in realm of academia, and a downstream commercial sector 
dominated by large and highly integrated pharmaceutical firms (Cockburn, 2005; 
Kahin and Foray, 2006). 
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Since the early 1980s, the industry structure has become considerably more complex. 
In the late 1970s biotech enterprises started to emerge as an intermediate sector 
between academic research institutions and the so-called ‘big pharma’. These new 
biotechnology companies straddled the historical for profit/not for profit divide. 
Although they were, profit-oriented organizations, biotech also had much tighter links 
to non-profit research institutions, with close personal, geographical, cultural and 
contractual ties to universities, research institutes and government labs (Cockburn, 
2005). 
A significant role in the founding of biotech firms was played by university scientists. 
In many instances, biotech companies were founded to exploit discoveries made by 
professors or groups of academic scientists (Arora and Gambardella, 1995). For this 
reason, biotech major assets consisted of the knowledge embodied in their founders 
and researchers (Pisano, 2006; Zucker and Darby, 2006a). Steven (2008) notes that it 
was not until the 1970s that scientific entrepreneurs began to occupy a central place in 
the entrepreneurial landscape by keeping one foot in the world of academia and 
another in the world of business.  
These new biotech companies forced some important adjustments to university-
industry relations.  By taking over a certain amount of research activity from both 
upstream and downstream entities, biotech heralded a new partnering mode of 
research with large incumbent firms relying heavily on their research tools and 
candidate molecules (Cockburn, 2005). Cockburn (2005) refer to this as a “vertical 
dis-integration” (p. 7), and report a number of interlinked economic and legal forces 
that may have caused it. In particular, one of the main reasons was the developments 
in law and administrative practices that brought much of molecular biology within the 
ambit of the patent system.  
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Among the legal and economic changes, the passage of the Bayh-Dole Act in 1980, 
which in the US enabled and encouraged the commercialisation of publicly funded 
research, played a particularly important role (Grimaldi et al., 2011; Mowery and 
Sampat, 2004; Mowery et al., 2001). After the Bayh-Dole Act, academic researchers 
were granted permission to file for patents and to issue licenses for intellectual 
property rights to other parties. As a consequence, despite  Mowery and Sampat (2004) 
charting the continuously increasing participation of US universities in the national 
patenting system since 1963, the entry rate of small firms is reported to have soared 
during the 1980s. Moreover, while biotechnology companies have become important 
participants in basic biomedical research, universities and other non-profit entities 
have increased their levels of participation in the patent system. In this way, market-
based competition started determining the overall rate and direction of technological 
progress. 
Despite their innovative mission, the great majority of biotechnology firms never 
managed to develop into fully integrated drug developers (Jensen, 2011). Typically, 
biotech enterprises were lacking capabilities in the later stages of the drug innovation 
process. Large pharmaceutical firms, conversely, found themselves in the opposite 
situation, i.e. whilst having trouble in adopting new biotechnology methods, they 
developed strong capabilities in the later stages of the innovation process. In this 
context, universities also controlled assets and skills that were to some extent 
complementary to those of both the biotech and the large firms (Jensen, 2011; Arora 
and Gambardella, 1995). 
In sum, because ‘big pharma’ and biotech firms controlled assets that were largely 
complementary, systematic collaborations between them arose (Arora and 
Gambardella, 1990). This created a stronger division of labour where, on the one side, 
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small biotechnology firms together with academia specialised in drug discovery, and 
large pharmaceutical firms on the development and marketing of drugs (Arora and 
Gambardella, 1994). As a result, the growth of the industry has hinged upon network-
like relationships based on extensive collaborations and a division of labour between 
these agents. In particular, given the tight relation between academic and 
biotechnology organizations that characterize the transformation of ‘R’ in ‘D’, any 
investigation cannot avoid to look at the combination of roles and actions undertaken 
by these actors at the early stage of the innovation process. 
 
Theoretical Background 
Nowadays, the research behind drug discovery is associated with a high level of 
knowledge complexity. Sources of knowledge are diverse and are derived from a wide 
variety of scientific fields and technological competencies. Generating and embodying 
new knowledge in products or processes is often conditional on the ability to access 
and then make sense of a significant variety of complementary research inputs  
(Allarakhia and Walsh, 2011). In the last decades, there has been a shift in the way 
innovation is conceived by authors in the economic arena. On the one side, at firm 
level, many scholars point out that the characteristics of the biopharmaceutical sector 
have helped pioneer the open innovation paradigm (Hughes and Wareham, 2010; 
Chiaroni, Chiesa and Frattini, 2011). At institutional level, there has been a move from 
the linear model to innovation systems. 
Open innovation 
The paradigm of open innovation has received substantial attention from scholars 
since its conceptualization by Chesbrough, Henry William (2003) as a counterpoint to 
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the traditional ‘closed innovation’ view. The open approach suggests that innovative 
outputs generate more easily in contexts with more openness towards external sources 
of knowledge. This openness encourages the fluidity of knowledge and information 
flows between firms (Ferreira and Teixeira, 2019; Chesbrough, Henry, Vanhaverbeke 
and West, 2006). Open networks have been found to be particularly beneficial in 
providing opportunities for knowledge creation through enhanced opportunities for 
‘spill-over’ effects or by increasing the likelihood of knowledge leaking through open 
network channels (Owen-Smith and Powell, 2004; Murray, 2002). 
The open business model requires the definition of a series of activities or value chain 
that will lead to a new product or service. Under the open paradigm, value creation is 
said to arise from multiple sources, and relates to strategic network theory and 
cooperative strategies (Dyer and Singh, 1998). Secondly, open strategies require that 
firms have one or more unique assets within the value chain allowing the firm to enjoy 
a competitive advantage and so capture a portion of that value (Chesbrough, Henry, 
Lettl and Ritter, 2018). 
Previous scholars showed that for a successful adoption of open innovation strategies, 
firms need to develop a number of open networking capabilities such as absorptive, 
multiplicative and relational capacity to deal with suppliers, customers, higher 
education institutions, and competitors (Gassmann, Enkel and Chesbrough, 2010; 
Perkmann and Walsh, 2007; Huston and Sakkab, 2006). In fact, the further firms open 
their boundaries, the further they become both interdependent and embedded within 
complex networks of interactions. Therefore, the emergence of the open innovation 
approach implies a system perspective which is “made up of components, linkages 
between the components, and dynamics” (Afuah and Tucci, 2003), (p.3). 
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The open paradigm has deeply influenced our thinking about the essential importance 
of firms’ internal and external knowledge environments, in contrast to the earlier focus 
on firms as ‘black boxes’ of closed relationships. Moreover, the mobility of trained 
workforces a more prepared transmission of information by data innovation has 
extended the event and the pertinence of overflows among firms and their outer 
surroundings. 
Innovation systems 
Innovation models have also followed the trend towards interactivity and openness 
which has characterised the industry in recent times. As such, there has been a shift 
from the linear model, where investments in science were assumed automatically to 
result in technical innovation, to a network mode of resource allocation which involves 
individuals, firms and institutions engaging in preferential and supportive actions. The 
conceptualization of the linear model of innovation is attributed to (Bush, 1945). The 
linear approach asserts that first there is basic research produced by universities, which 
gradually diffuses out into society and the economy. Incumbent firms then absorb the 
commercially relevant elements of university research and develop them into 
knowledge applications and innovation. In this way, within the frame of linear 
innovation, the relationship between knowledge and innovation is sequential in nature. 
With the evolution of industrial contexts, the linear model of innovation has become 
challenged by non-linear models, in which basic research and innovation are coupled 
together not in a ‘first-then’, but in an ‘as well as’ and parallelised relationship  
(Carayannis and Campbell,2012). 
The changes in the relationship between ‘science’ and ‘business’, both within the firm 
and also between industrial and institutional environments, have been studied in the 
literature on the systems of innovation. The concept was introduced as ‘Innovation 
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Systems’ by the evolutionary economist Bergt-Åke Lundvall to emphasise the 
interactions between firms, organisations and policymakers (Freeman, 1995; 
Lundvall, Bengt-Ake and Dosi, 1988; Lundvall, Bengt-Åke, 2010). Based on the joint 
work of Lundvall, Freeman and Nelson, it became ‘Systems of Innovation’ (Dosi, 
1999; Nelson, R. R., 1993; Lundvall and Dosi, 1988). The system approach is about 
the determinants of innovations, not about their consequences. The two main areas of 
application and contribution for systems of innovation literature concern the 
regional/national development, and the public policy for science, technology and 
innovation (Boschma, 2004; Edquist, 2001). Studies about systems of innovation 
usually refer either to one specific ‘territorial level’ (e.g. ‘national systems of 
innovation’) or to one specific technology or industrial branch (e.g. ‘sectoral systems 
of innovation’). However, due to the processes of political decentralisation, 
globalisation, and some paradigmatic changes in certain technological fields such as 
biotechnology, the borders of such systems have blurred. 
Nowadays, more of the functions at financial and policy levels are located across 
various territorial and sectoral levels. As a result, innovation systems have undergone 
a process of reconfiguration and there has been a substantial change in the role 
attributed to certain organisations in the systems. In particular, in the context of the 
Triple Helix literature, the role of universities was highlighted as a locus of national 
knowledge-intensive networks. 
Traditionally, the role of academia centred on teaching and producing basic research, 
without any interest in the practical use of knowledge and innovation. This model of 
university-based knowledge production is known as ‘Mode 1’ (Gibbons, 1994). In the 
last decade, Etzkowitz and Leydesdorff (2000), emphasised the core role of 
universities as a central model for knowledge production and innovation, where three 
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“helices” – identified as academia (universities), industry (business), and state 
(government) – intertwine and thereby create a national innovation system. Etzkowitz 
and Leydesdorff (2000) refer to “university-industry government relations” and 
networks, putting a particular emphasis on “trilateral networks and hybrid 
organizations”. 
In the Triple Helix model, universities are deemed to have a third mission, defined as 
the transition from educating individuals to shaping organisations. This 'third mission' 
idea was first presented as an expansion of the scholarly world to other market-
arranged advancements and information move (Sánchez-Barrioluengo, 2014; Chen 
and Lin, 2017). As a consequence, universities are now viewed as engines of economic 
growth through a recognition of the strategic role of science (Hussler, Muller and 
Rondé, 2010). Universities are recognized in a position of being engaged through 
knowledge transfer in societal and economic growth activities. Universities have 
therefore become much more oriented to the commercialisation of research, and 
consequently, academia is witnessing a functional shift from basic to applied research 
(Perkmann and Walsh, 2007). Powell and Owen‐Smith (1998) go as far as to argue 
that the separation of the scientist in the academic world and the technologist in the 
private arena no longer holds in the life sciences. 
 
Theoretical Framework 
The changes at institutional and theoretical levels have made difficult, from a research 
perspective, the tracking of innovative ideas and conversion into technological 
knowledge and innovation. The new pharmaceutical reality is, in fact, still 
characterised by high risk and appropriability issues, and research activities are 
dominated by high levels of uncertainty in terms of both generating knowledge and 
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then applying this knowledge to downstream activities. Scholarships in innovation and 
entrepreneurship have made significant strides in examining how the macro-
knowledge context relates to the micro-underpinnings of new firm formation. In this 
context, the role that scientific human capital plays is an essential element for 
competitive success. 
Based on these premises, in the next paragraph, we present the theoretical framework 
in which the three essays of this doctoral work have been framed. I illustrate the main 
elements of the knowledge spill-over theory of entrepreneurship, which is the main 
theory linking the three empirical works. Furthermore, I present the main features of 
two other connected disciplines – scientific and technical human capital, and scientific 
entrepreneurship. Based on these, I identify the research gap and the rationales to 
formulate my research questions. 
Knowledge Spillover Theory of Entrepreneurship 
Entrepreneurship scholarship is focused on the process by which individuals discover 
and act on entrepreneurial opportunity. According to (Shane, Scott and Venkataraman, 
2000), (p.218), the field of entrepreneurship is concerned with “the sources of 
opportunities; the process of discovery, evaluation, and exploitation of opportunities; 
and the set of individuals who discover, evaluate, and exploit them”. For long time, 
the literature has focused on the characteristics specific to individuals in order to 
explain the ability to either exploit or create entrepreneurial opportunities. Traditional 
theories have considered entrepreneurial opportunity as exogenous, and then implied 
that the likelihood of becoming an entrepreneur was attributable solely to differences 
in the propensities, proclivities and inclinations of the individual entrepreneur. 
Initiated by Audtrescth in 1995, the Knowledge Spillover Theory of Entrepreneurship 
(KSTE) takes a different starting point (Audretsch, 1995). Rather than on individuals, 
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the focus is on the organisational context as a source of knowledge creation and 
entrepreneurial opportunity. In particular, the KSTE theorises how and why 
knowledge spills over, and in what manner entrepreneurship acts as the mechanism by 
which knowledge evolves into economic knowledge within a given framework. 
Interestingly for the purpose of this thesis, the theory highlights that entrepreneurial 
opportunity is derived from the creation of knowledge that has not been fully 
appropriated within the incumbent organisation from which that knowledge 
originated, for example the university. Thus, the entrepreneurial activity of scientific 
founders is seen as the conduit facilitating the spill over of that knowledge into the 
market arena (Audretsch and Link, 2019; Audretsch and Keilbach, 2007). 
The KSTE brings together contemporary theories and thoughts of entrepreneurship 
with prevailing theories of economic growth. This theory poses on the scholars who 
highlighted the characteristics of knowledge as distinct from the ‘normal’ economic 
goods. As Arrow (1962) emphasised, the first aspect of the knowledge concept 
involves its non-excludability, which means the inability to exclude others from 
accessing and using that knowledge. The second element refers to the non-
exhaustibility of knowledge, meaning that its use by one party does not preclude others 
from using that same knowledge. The third point refers to the high degree of 
uncertainty, which makes it difficult, if not impossible, for firms to assign an expected 
value to various outcomes. Furthermore, knowledge is not a given or a free good at 
everyone’s disposal, and thus only a few people know about a particular scarcity or a 
new invention, (Hayek, 2007; Katz and Shapiro, 1985; Stiglitz, 1999). Taken together, 
these characteristics increase the propensity for knowledge to spill over from the firm 
or the organisation in which it was created to other third parties who can access that 
knowledge for a cost less than its value. 
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The way in which knowledge spills over between organisations has attracted the 
attentions of many scholars. In particular, this has been central for the development of 
endogenous growth theories (Romer, 1986; Lucas Jr, 1993). Compared to exogenous 
models such as the Solow model, endogenous models make explicit that knowledge 
is a key factor of production, along with the traditional factors such as capital and 
labour (Solow, 1956). However, the assumption in the endogenous model of growth 
by  Romer (1986) is that spill over from investment in new knowledge results 
automatically in commercialisation. In particular, the Romer model refers to the 
geographical location and proximity to other firms as a source of purposeful 
investment in R&D. In contrast, the premise of the KSTE theory is that the spill over 
of knowledge from its source is impeded by the so-called ‘knowledge filter’ (Acs et 
al., 2004; Audretsch and Keilbach, 2007). 
Since new ideas and knowledge are characterised by uncertainty, the knowledge filter 
is the reason why they may not be pursued and instead remain uncommercialised by 
incumbent organisations. Alvarez (2003) distinguishes between decision-making 
under uncertainty (which is typically associated with organisational inertia) and 
decisions taken under risk (which instead enables the incumbent firm to calculate 
expected outcomes along with a probability distribution associated with those 
outcomes) (Alvarez and Barney, 2005; Alvarez, 2003). At an institutional level, 
regulations and legal restrictions may likewise account for a portion of knowledge 
filter. However, the aspects most often regarded as the source contributing to the 
knowledge filter are the Arrowian conditions inherent in the knowledge concept such 
as uncertainty, asymmetries, and high costs of transaction (Ahmetoglu et al., 2017). 
Therefore, the KSTE argues that due to the presence of the knowledge filter, 
investments in science and research do not automatically spill over into the market. 
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Consequently, the knowledge filter is the reason why investments in R&D do not 
automatically influence economic growth and employment generation as hypothesised 
by endogenous growth models. There is, of course, a correlation between investments 
and economic growth, although Audtresch (2008)  argue that this is not maintained at 
lower levels of aggregation (Audretsch and Keilbach, 2008). The so-called ‘European 
Paradox’ represents an empirical case for the knowledge filter, as it refers to the 
existence of economic stagnation even in countries in which investments in education 
and research are high (Audretsch, 2009; Audretsch and Keilbach, 2008). No 
systematic relationship has been revealed between R&D expenditure and GDP-
growth, whereas a positive relationship between entrepreneurship and subsequent 
economic growth has been found, and traditional theories have failed to disentangle 
the reasons why small firms with low investment in knowledge creation are able to 
generate innovative output (Wennekers and Thurik, 1999; Braunerhjelm et al., 2010). 
In sum, what has been regarded as the missing link in endogenous models, and that the 
KSTE has explained, is a failure to incorporate one of the most crucial elements in the 
growth process: the transmission of knowledge through entrepreneurship 
(Braunerhjelm et al., 2010). 
In the KSTE, a higher level of entrepreneurial activity corresponds to a greater portion 
of ideas flowing through the filter and being transformed into economic knowledge. 
Also, by promoting a shift from the firm level to the contextual level in which 
scientists becomes entrepreneurs, the KSTE provides an answer to the so-called 
‘appropriability problem’. 
In the traditional economic approach, the issue revolves around how firms investing 
in knowledge creation can best appropriate the economic return from that investment 
(Arrow, 1962). The KSTE takes a different perspective, which involves the 
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transformational function of humans, rather than the firms, constituting an economy. 
Therefore, from the perspective of the KSTE, the question of appropriability has 
become: “How can scientists with a given endowment of new knowledge best 
appropriate the returns from that knowledge?” (Audretsch, Aldridge and Oettl, 2009) 
(p.174). The answer provided by the KSTE theory is that through entrepreneurship, 
scientists are able to appropriate returns from knowledge and the ideas that they have 
created within the incumbent organisations, which also financed such process of 
knowledge creation. Levin and Stephan (1991) suggest that this appropriation also 
depends on both the career trajectory as well as the lifecycle of the scientist. Scientist 
lifecycle models suggest that early in their careers scientists invest in human capital 
in order to build reputation (Levin and Stephan, 1991). More specifically, the 
appropriability question confronting academic scientists can be investigated by taking 
the perspective of two important streams of research: the literature on scientific and 
technical human capital, and that of scientific entrepreneurship. 
Scientific and technical human capital 
Theorists define scientific and technical human capital (S&T human capital) as the 
“sum of scientific, technical and social knowledge, skills and resources embodied in a 
particular individual” (Bozeman and Corley, 2004), (p.599). It includes both human 
capital endowments, such as formal education and training included in human capital 
models (Schultz, 1963; Becker, 1962) as well as the social relations and network ties 
analysed by social capital theories (Coleman, 1988; Bourdieu, Pierre and Wacquant, 
1992; Bourdieu, P., 1986). Despite this separate approach, scholars have struggled to 
disentangle the practice of science from the career of growth of scientists. Therefore 
S&T human capital comprises of the overall skills, knowledge, and social relations 
needed to participate in science. 
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Scientific human capital primarily consists of the scientists and inventors within a 
firm. Skilled and talented knowledge workers are critical determinants of innovation  
(Merton, 1973; Nelson, K. and Nelson, 2002). However, with the birth of science-
intensive industries, an increasing number of scientists from academia began actively 
contributing to technological activities within firms. In addition, firms began attracting 
scientists to join their organisations, offering incentives to publish their research 
findings and to collaborate with leading academic scientists (Helfat et al., 2009). 
Therefore, following the evolution of the biotechnology sector and links within 
universities, the careers of scientists co-evolved to reflect the changes occurring in 
models of R&D, as well as the new norms in the legislative landscape. 
Traditionally, an academic researcher worked at a university or independent research 
laboratory (Partha and David, 1994). Particularly in the early stage of their career, the 
goal for an academic scientist was to establish the priority of a discovery through 
publications in scientific journals. Recognition by peers and paper citations were other 
factors motivating researchers in their tenure stage (Merton, 1957). With maturity, 
scientists sought to appropriate the economic value of such knowledge, and therefore 
the decision to commercialise might depend on the value of the reputation they had 
built (Levin and Stephan, 1991). 
With the advent of the knowledge economy and the transition to networked processes 
of innovation, the traditional aspects of the academic profession have also changed. 
For example, often academic inventors now patent their research before openly 
presenting it to the public at large, through publications (Boardman, 2008; Boardman 
and Ponomariov, 2009). Firms also seek to collaborate with research universities by 
adopting open science strategies. In order to resolve the differences between scientific 
objectives and industrial goals, corporations have developed different models of R&D 
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organisation and human resource strategies. A major challenge for many high-
technology firms and institutions has been the development of collaborative structures 
to engage academic and industrial scientists in joint knowledge production (Bozeman 
and Corley, 2004). Universities have contributed to closing this gap by providing 
access to research and development facilities, enhancing the production of knowledge 
that facilitate the understanding of practical issues, and providing services which 
ensure the assimilation of new technologies. Overall, the nature of academic and 
industrial work has coevolved along with changes to innovation models, such as the 
move from a technology push to a market pull, and a network of collaborative 
activities between organisations of different kinds (Rothwell, 1992; Liyanage, 
Greenfield and Don, 1999). 
Scholars such as Henderson and Cockburn (1994); Zucker, Darby and Armstrong 
(1998) focused their attention on the study of firms’ ties to the scientific network and 
the way these influence companies economic performance, and technological 
progress. Ties and modes for spill-overs were categorised in three main types: 
publication and co-authorship; proximity to star scientists; and movement of scientists. 
With regard to the first type, scholars in this field have argued that, especially in 
periods characterised by shifts in the technological paradigm, such as the rise of 
biotechnology, publications are a crucial to make this transition successful (Arora and 
Gambardella, 1994; Liebeskind et al., 1996; Henderson and Cockburn, 1994). 
Moreover, Zucker and Darby (1998) argue that ties to science arise largely through 
the proximity and participation of ‘star scientists’. Star were scientists with 
exceptional scientific records as defined based on the number of publications and gene 
discoveries. The relevance of firms ties with Stars was supported by the degree of 
success of such firms, which was demonstrated to be largely dependent on the 
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involvement of these scientists. Lastly, a third tie is characterised by the movement of 
human capital. Partha and David (1994) assert that the “export of scientists and 
engineering from the academy to industrial research is potentially the most important 
and salutary among the mechanisms available for effecting knowledge transfers” 
(p.511). 
Furthermore, the S&T literature has contributed to our understanding of the impact of 
involvement in science on technical productivity. In this context, Murray showed that 
science and technology networks co-evolve and overlap through a number of avenues, 
such as co-publishing and citation, co-patenting, consulting, advising, movement of 
human capital from academia to industry, proximity to ‘star’ scientists, licensing and 
company founding (Murray, 2002). Furthermore, Breschi and Catalini (2010) 
explored the co-evolution of science and technology and found that author-inventors 
who bridge the boundaries between science and technology domains are crucial for 
allowing connectivity. Furthermore, Gittelman and Kogut (2003) show the importance 
to biotech companies of ties with open science through boundary-spanning ‘. In this 
context, bibliometric and social network analyses are used to study, respectively, the 
science–technology overlap (Murray, 2002) and the evolution of scientific 
collaboration between scientific and technological communities (Barabâsi et al., 
2002). In these contributions, the different actors and groups that shape new 
technologies may belong to scientific and/or technological communities, while being 
affiliated to organisations which can be positioned in the triple helix of university–
industry–government relations (Blosch and Preece, 2000). Therefore, by focusing on 
actors it is possible to move from people to their corresponding groups, organisations 
and the triple helix. Scientific entrepreneurship constitutes an essential determinant in 
the emergence of a system of innovation and represents the key element in connecting 
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the distinct but overlapping roles of individuals, firms and institutions in the 
pharmaceutical industry. 
Scientific entrepreneurship 
The features of biotechnology as a scientific field can be related to those of scientific 
entrepreneurs. Concepts such as ‘scientific entrepreneurship’ or ‘entrepreneurial 
scientist’ have not been commonly used in the scientific literature. An early account 
of this phenomenon was provided by Ben-David (1971) in the context of American 
universities and the process of ‘professionalisation’ of scientists. Specifically, David 
relates the concept of scientific entrepreneurship to academic scientists conducting 
professional, large-scale research with graduate students, including paid-for research 
(Oliver, 2004). The birth of academic entrepreneurship has mirrored the increasing 
integration of science with different sectors of the economy (Lacetera, 2009b). In the 
course of this change, academic entrepreneurs act as a link between the worlds of 
academia and private enterprise (Lacetera, 2009a). 
The approaches followed by scholars can be categorised under three main theoretical 
approaches which also confirm the extensiveness of the definitions in use. The first 
prevailing view stems from the idea of business creation by academics (Wright et al., 
2009; Shane, Scott Andrew, 2004). Some authors have included in this category 
companies created from the intellectual property generated inside universities, 
irrespective of whether the entrepreneur was an academic employee (Hayter, 2011). 
A second approach is provided within the context of the literature on knowledge 
transfer.  (D’Este, Mahdi and Neely, 2010) describe an academic entrepreneur in the 
following way: “The literature on university-industry technology transfer defines an 
academic entrepreneur as a university scientist who engages in the commercialisation 
of the result of his/her research, largely by patenting and/or setting up a business” 
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(p.2). From this standpoint, the authors included the contacts that academics have with 
business entities that are the basis of monetary value creation. ‘Hard activities’, such 
as patenting, licensing and spin-off formation, as well as ‘soft activities’ such as 
publishing, grant seeking and contract research, are included under this commercial 
definition (Cantaragiu, 2012; Philpott et al., 2011). Furthermore, an interesting line of 
inquiry was developed by Zucker in relation to ‘star’ scientists who work 
collaboratively with firms’ scientists (Zucker and Darby, 1998). The third theoretical 
approach to scientific entrepreneurship employs value-based definitions and entails a 
broader view of entrepreneurship as the creation of societal value. Under this 
framework, the scientific entrepreneurship concept refers to scientists who 
acknowledge the commercial value of their discoveries and act to legitimise and 
commoditise their findings, thereby enabling commercialisation (Oliver, 2004). In this 
approach, a key feature of the entrepreneurial scientist is their claim for patent rights 
over academic research in order to licence rights to future use by third parties (Oliver 
and Liebeskind, 2003). 
In the scientific literature, the terms ‘academic entrepreneur’ and ‘academic 
entrepreneurship’ are treated and theorised in different ways. Traditionally, academic 
entrepreneurship was intended as ‘university spin-off’ or an institutional transfer of 
research or technology aimed to start new ventures (Shane, 2004). According to 
Beckman and Cherwitz (2009), academic entrepreneurship can be defined as an 
‘intellectual enterprise’ created by universities that cooperate with local communities 
to create new values or ideas. Shane (2004) explains the five advantages of an 
academic entrepreneurship spin-off: (1) to “encourage economic development,” (2) to 
“enhance the commercialization of university technologies,” (3) “spin-offs help 
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universities with their mission,” (4) “spin-offs are high potential companies,” (5) 
“creating spin-offs is more profitable than licensing to established companies.” 
 
Due to the characteristic of ‘producing knowledge’, the definition of academic 
entrepreneurship is close to that of ‘academic firm’, which sees an academic 
entrepreneur operating simultaneously as intellectual actor and as entrepreneurial 
actor (Campbell and Guttel, 2005). Therefore, an ‘academic entrepreneur’ is defined 
as an occupational profile for an actor who is scientifically active and at the same time 
working as an entrepreneur. Based within an integrated network of academic and 
business organizations, an academic entrepreneur distinguishes for an entrepreneurial 
thinking and actions and the creation of earnings and profit through self-employment. 
By bridging the science and business domains, academic entrepreneur creates 
economic value the utilisation of knowledge. By playing this role, academic 
entrepreneurs derive direct utility from research activities that precede the completion 
of a project and the monetary returns from its commercialisation (Lacetera, 2009). 
In conclusion, with the development of new models of innovation the academic 
entrepreneur increasingly becomes a central actor in facilitating a cooperative and 
targeted exchange of knowledge and technologies between the academic world and 
the world of private enterprise. In this context, the academic entrepreneur also 








CHAPTER 2: Rationales and Research Questions 
 
The variety of theoretical arguments landscaping this work suggest that a clear 
perspective and definitions of the main arguments contained in the three essays of this 
thesis should be stated. A first element is the definition of scientific entrepreneurs, 
which in the context of my essays are also called ‘scientific founders’. 
According to the knowledge and technology transfer literature, this thesis adopts a 
broad approach to the analysis of scientific entrepreneurship. In the context of the 
empirical essays, the focus is not on the motives that lead scientists to become 
entrepreneurs, but rather on the means by which knowledge is transferred from 
scientific to commercial domains. As illustrated in the theoretical chapter, I take the 
view of KTSE theory, which sees the entrepreneur as a conduit facilitating the spill 
over and commercialisation of knowledge which hasn’t been fully appropriated by the 
organisation which created it. 
Based on these premises, I define scientific founders or entrepreneurs as: 
Scientists, with heterogeneous career trajectories within academia and/or industry, 
engaging in the commercialisation of research that hasn’t been appropriated nor used 
by the organisation(s) from which it originated. 
The proposed definition is based on KSTE theory by viewing entrepreneurship as a 
conduit to the transfer of knowledge which hasn’t been converted, yet, into product. I 
bring together the literatures on scientific and technical human capital by highlighting 
the heterogeneous pathways followed by scientific founders across networks of 
organisations. This point is relevant because it provides a shift in the way that 
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knowledge transfer can be studied, as compared to the predominant view by extant 
scholars. In fact, the approach adopted in this thesis is to identify scientific 
entrepreneurs from their organisations, and not vice versa. 
Based on these premises, in both Essays 1 and 2 I take biotechnology companies as a 
starting point from which I trace the identity of the scientists who contributed to their 
foundation. This element represents an innovative approach to the study of the 
knowledge transfer phenomena. In the extant empirical literature, much attention has 
centred on academics who start spin-off companies and, more generally, on the 
multiple ways in which universities become involved in activities shared with actors 
at an industrial level. This thesis takes a different perspective, focusing instead on 
biotechnology ventures that create new drugs (Essays 2 and 3) and achieve IPOs 
(Essay 3). Based on these, I trace back the identities of the scientists whose innovative 
ideas have flowed into correspondingly innovative products. 
 
Rationale for Essay One 
Previous chapters have revealed a variety of theoretical and institutional lenses that 
can be adopted to study the phenomenon of how science is transformed into products, 
as well as the role that scientific entrepreneurs play in such complex processes. The 
Knowledge Transfer literature suggests that there are several other aspects of 
academic life which can be classified as entrepreneurial activities. The lenses offered 
by the KT approach allow the appreciation of a broader dynamism with respect to 
academic engagement in different entrepreneurial activities than simple spin-off 
creation (Franzoni and Lissoni, 2009; Jain, George and Maltarich, 2009). It has been 
highlighted that academic involvement in knowledge transfer activities is a 
precondition for subsequent spin-off creation (Tijssen, 2006), and furthermore (D’Este 
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and Patel, 2007) found that other knowledge-transfer activities are equally, or even 
more, important than company creation, both in terms of frequency and economic 
impact. 
Based on these findings, KT provides the missing link between the theories illustrated 
in the previous chapters and the empirical examinations which will follow in Essays 
2 and 3. Knowledge transfer is defined as movement of know-how, technical 
knowledge, or technology from one organizational setting to another (Roessner, 
2002). In Essay One, I investigate the nature of knowledge, and the relational context 
of sources and recipients involved in transfer activities. These elements are revised 
with the specific aim of clarifying what drives the adoption of different transfer modes 
of knowledge transfer and to converge on shared elements. 
Essay One – Research questions 
The main research questions guiding my review are: 
1. What determines the movement of knowledge between university and industry?  
2. What are the characteristics of the transport mechanism? 
Objective: To gain a better understanding of academia–industry interactions and to 
explore the conduit of knowledge transfer to bring innovation to market. 
 
Rationale for Essay Two 
In the previous chapters I highlighted the complex set of relationships guiding the 
efforts of scientists and organisations, and the seizing of entrepreneurial opportunities 
to capitalise on research discoveries. It was shown that the extent of public-private 
interaction in drug development has been accompanied by several institutional 
changes in the innovation process and the distribution of innovative work between 
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university, government and industry in the last decades. Furthermore, at a theoretical 
level, KSTE theory has offered a relevant point of view in understanding how 
knowledge spills from universities to the private sector, thanks to the entrepreneurial 
initiatives of scientists. In this context, it was evident that a core element was the 
knowledge which was not appropriated within the organisation from which it 
originated. Secondly, it was recognised that due to the presence of the knowledge 
filter, investments in R&D do not automatically result in innovation. Despite this, a 
relevant quantity of resources is spent every year at global level, to foster and support 
innovative activities of universities and the transfer of potential innovative ideas to 
companies. Yet elements such as the financial aspects related to the transfer of 
knowledge and the financing of basic science have been studied to a lesser degree, 
both at theoretical and empirical levels. Furthermore, most of the scientific production 
has looked at the use of governmental funding from a macroeconomic perspective. 
Recently, in light of the key role played by universities and governments in the 
production of basic research, new questions have been raised about the rates of return 
from public spending to support blue-sky research. Budgetary concerns and high 
prices of medicines have fuelled proposals to recoup profits from government-funded 
drugs and to avoid taxpayers having to pay twice – first with taxes for publicly funded 
research, and then through monopoly of prices or restricted access (Sampat and 
Lichtenberg, 2011; Alperovitz and Daly, 2009). Based on these premises, in Essay 
Two, I explore the relation between funding inputs and research outputs by centring 
on the scientific production of scientists and founders of biotech firms, taking 
advantage of the acknowledgment sections of the publications by the scientific 




In accordance with the lenses adopted by this thesis, which focus on the role played 
by individuals in the transfer of knowledge between academia and industry, in Essay 
Two I contribute to the debate by providing a new perspective on the finance in 
innovation. Here, rather than analysing research budget top-down, I trace back to the 
financial origin of innovative ideas, as disclosed within the literature realized before 
the involvement of scientists in entrepreneurial activities. In doing so, the main scope 
was to shed light on the financial contributions given to science that go on to be 
successfully developed into pharmaceutical products. 
Essay Two – Research questions 
1. What is the nature of the financial support acknowledged in the publications 
by biotech founders? 
2. What is the distribution of funding organisations across countries and 
disciplines? 
3. To what extent does funded research have a higher impact in terms of article   
citations? 
Objective: To analyse the nature and the scope of the financial contribution 
acknowledged by scientists involved in the foundation of biotechnology companies 
which lead to biopharmaceutical discoveries. 
 
Rationale for Essay Three 
Founders of biotechnology companies are the focal element of many theoretical and 
empirical instances. At the individual level, scientific founders act at the interface 
between science and commerce. At the organisational level, the biotechnology 
companies, built upon the founders’ scientific backgrounds, act as intermediaries 
between university research and the commercial arena. 
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KSTE highlights the critical role played by scientists who engage in entrepreneurial 
activities and function as a conduit for unappropriated knowledge to transfer from 
scientific to commercial domains. On the other side, the elements from the scientific 
and technical human capital literatures, pointed out the variety and heterogeneity of 
career trajectories which characterize the scientist professional life cycle. The 
knowledge transfer literature rationalized these theoretical underpinnings by shifting 
the attention to the channels and processes by which knowledge is transferred and 
contemporarily transformed into innovation (Essay One). Lastly, the potential for the 
use of publication data was highlighted as a mean to analyse the financial aspects 
related to the creation of knowledge by scientists (Essay Two). 
In this final work the elements by previous literature, including the previous essays of 
this thesis, are employed to investigate another aspect of the relation between the “R” 
and “D”: the appropriability issue. To this end, I take advantage of the patent 
documents filled by the biotechnology founders in order to investigate the relation 
between founders’ scientific human capital and patent ownership. 
Essay Three – Research questions: 
1. What is the scientific human capital upon which European biotechnology firms 
are created? 
2. To what extent is the assignation of intellectual property rights sensitive to:  
1.  the inventor professional career; 
2.  scientific experience; and 
3.  patent characteristics? 
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Objective: To analyse the career trajectories and research backgrounds of scientific 
biotechnology founders, and to explore how these affect the assignation of intellectual 




















CHAPTER 3: Methods and Philosophy 
 
Research philosophy 
As noted by Johnson (2006), researchers need to be aware of the philosophical 
commitments they make through their choice of research strategy because they may 
influence not only our understanding but also what we are investigating. Paradigms 
may be defined as the worldviews or belief systems that guide researchers (Guba and 
Lincoln, 1994). From the second half of the nineteenth century, two major approaches 
to the study of reality have become predominant, and form part of an ideological 
conflict which is still ongoing: the positivist/empiricist approach versus the 
constructivist/phenomenological orientation. The positivist paradigm forms the basis 
of quantitative methods, while the constructivist paradigm underpins qualitative 
methods (Guba and Lincoln, 1994). The qualitative-quantitative divide plays out at 
different levels, with various peculiarities in terms of epistemological issues, 
ontological concerns and the role of theory (Bell, Bryman and Harley, 2018). The 
quantitative approach implicitly assumes the existence of an objective world, 
independent from our thought, a ‘res extensa’ standing autonomously from human 
reasoning, or ‘res cogitans’ (Mariani, 2011). The object of research is, thus, 
‘discovered’ through a deductive approach towards data, which are collected in order 
to test hypotheses on the basis of previous theoretical reasoning. In contrast, 
qualitative research emphasises an inductive process, drawing generalisable 
inferences (theories) from observations. Here the focus is on the understanding  
(Weber, 2009) of human behaviour as distinct from the subject of the natural sciences. 
This requires a different logic to be applied in order to reflect the distinctiveness of 
humans as the subject matter of research. Drawing on Creswell and Poth (2016), in 
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Table 1 I provide brief a summary of the philosophical assumptions characterising two 
main paradigms. 
 Positivist Paradigm Phenomenological Paradigm 
Ontology (nature of reality) Reality is objective and 
singular. Social phenomena 
exist independently of social 
actors. 
Reality is subjective as seen by 
participants in a study. The 
world is socially constructed 
and can only understood by 
examining the perceptions of 
the human actors,  (Collis and 
Hussey, 2013). 
Epistemology (the relationship 
of the knower to the 
knowledge) 
Focus on causality and 
generalisation. The researchers 
are independent from that 
which is being researched. 
Observable phenomena and 
subjective meaning provide 
acceptable knowledge. 
Axiology (role of values in 
enquiry) 
Independent and objective 
stance. Positivist scholars 
believe that the object they are 
studying is unaffected by their 
research activities. 
Researchers are bound to their 
values that help determining 
what are recognised as facts 
and the interpretations which 
are drawn from them  (Collis 
and Hussey, 2013). 
Generalisation Time- and context-free 
generalisations are possible. 
Time- and context-free 
generalisations are not 
possible. 
Causal Linkages There are real causes that are 
temporally precedent to, or 
simultaneous with, effects. 
It is impossible to distinguish 
causes from effects. 
Logic Deductive logic: from the 
general to the particular, and 
emphasis on a priori 
hypotheses (or theories). 
Inductive logic: from the 
particular to the general, and 
emphasis on ‘grounded’ 
theories. 
Table 1: Philosophical Assumptions 
Despite all this, the distinction between the two paradigms is not as straightforward as 
it might seem. Boundaries between philosophical assumptions are not markedly 
defined, and such labelling (deduction/positivism, induction/interpretivism) can be 
misleading (Saunders, Lewis and Thornhill, 2009). 
Thus, according to Tashakkori and Teddlie (2010), in this dissertation I believe the 
importance and predominance of the research question over the paradigm. This 
pragmatic position postulates the predominance of the research question over the 
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epistemology, ontology and axiology I adopt, as one may be in turn more appropriate 
than the other for answering particular questions. 
Therefore, from my research questions, it is noticeable how the philosophy behind the 
present study is mainly driven by a positivist orientation toward a deductive 
investigation, and thus the study is based on a quantitative approach. In fact, my 
hypotheses have been previously settled in order to give justifications and 
fundamentals through what is discovered. The assumptions will be first tested on a 
conceptual basis and then empirically validated in order to obtain an objective and 
‘credible’ result where cause-effect relationships are made clear and generalisations 
are made possible. 
The ontological assumptions I make about the world I investigate are towards 
objectivism. The position that I assume towards reality, conceives it as an external 
entity separated from social actors. In fact, the analyses do not include the researcher’s 
perceptions or those of individuals. Even though the process of knowledge 
transformation at the origin of the innovation process takes place individually, my 
believe is that there exists a social phenomenon and their meanings have an existence 
that is independent of social actors  (Bell, Bryman and Harley, 2018). Furthermore, 
the epistemological position of this dissertation is towards positivism; only 
phenomena that we can observe will be considered as credible data. Facts (rather than 
impressions) constitute the observable social reality (Saunders, Lewis and Thornhill, 
2009). Lastly, my emphasis is on gathering quantifiable observations to enable 
statistical analysis and ‘free-values’ considerations. Thus, my axiological assumption 




This study follows a mainly quantitative approach in which theories and hypotheses 
will be tested throughout a research strategy. As proposed by Saunders et al. (2009), 
I have first delineated a proposition, as a result of the literature review, about the 
relationship between some concepts and variables. More precisely, I believe in a 
positive relation between publicly funded scientific research and the creation of start-
ups and spinoffs in the biotechnology sector. Secondly, I have expressed my 
hypothesis in operational terms and further details on the measurement of each 
variable will be provided in the data collection paragraph. In particular, I believe in 
the existence of a link between the scientific background of the founders of such 
companies, and their public support and scientific achievements. Thirdly, I adopt a 
strategy, as I will illustrate in the following paragraph, to respond to each operational 
question and hypothesis. Finally, I examine the outcome of my research, either to 
confirm the hypotheses or to indicate the need for a modification to the theory. 
 
Research strategy 
According to Saunders et al. (2009), the research strategy is the "general plan of how 
you will go about answering the research questions" (p.74). For  Ritchie et al. (2013), 
the relationship between research design, theory and data collection is reiterative, and 
each phase should inform and be informed by the others. Therefore, the literature 
review operates as a strategic plan that logically turns the original research questions 
into empirical projects. The purpose of my study is to establish and explain the causal 
relations between variables and concepts. The strategy adopted here could be 
described as ‘explanatory’, since purpose of enquiry may change over time, and 
consequently, the study could also be termed descripto-explanatory, as a result of the 
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fact that I took advantage of previously available data to infer and test the validity of 
certain theoretical assumptions, such as those of KSTE theory. In particular, the 
research makes use of documents, previous literature, reports and administrative 
documents, so that the nature of the answer to our research question could be 
constrained by the nature of the information collected. In terms of methodology 
choice, multiple methods were employed for data collection. In particular, different 
sources and collection techniques were combined from previously published studies 
(see data collection paragraph). Another relevant aspect to mention is that this study 
is not aimed at representing the development or change of the phenomena over time. 
However, I am aware that my understanding will be necessarily time-constrained. The 
structure of the industry, the regulatory framework and the economic outlook will 
certainly determine some of my conclusions, even though it was my intention to use 
those empirical observations only as a confirmation of previous theoretical hypothesis. 
 
Sampling 
The quantitative research paradigm emphasises the importance of generalisability and 
reliability (Henn, Weinstein and Foard, 2005). The aim is to apply the relationship 
obtained between variables to the general, i.e. the population. For these reasons, the 
sampling procedure is an essential part of quantitative research. One approach to 
identify appropriate samples is to start from the whole population and then specify the 
study group to work with. The researcher should pay special attention to presenting 
information about the characteristics of the sample, and include details on sampling 
strategies which would enable others to repeat the research (Henn, Weinstein and 
Foard, 2005). In the context of my empirical examinations, a specific sampling 
strategy was employed to ensure the generalisability, reliability and repeatability of 
40 
 
the research findings. 
In both essays, a deductive strategy to sampling was employed. The starting point was 
represented by a population made of biotechnology companies headquartered in the 
UK (Essay Two) and in Europe (Essay Three) which had created at least one drug 
development project. Drug originator companies were defined as “when the drug is 
conceptualized, discovered and initially developed and the intellectual rights 
originate” (GlobalData, 2020). 
Samples employed in Essays two and three were identified from the electronic 
database by GlobalData PLC, a digital company providing data and analysis for 
consumer, technology and healthcare businesses. The GlobalData database comprises 
of information on companies’ pipelines with a focused and comprehensive coverage 
of the drugs in development. The samples were narrowed down by applying a series 
of criteria which helped to identify the relevant units of observation. In Essay Two, an 
initial selection criterion was that the UK-based biotech firm had received Venture 
Capital (VC) support. This condition was applied because the purpose of the essay 
was to analyse the early stage of the pharmaceutical R&D. In fact, contributions by 
venture capitals are considered key for the early development of promising drugs. The 
access to VC financial tools was employed in the essay as a signal of successful and 
promising development of inventions into innovative products. 
In contrast, in Essay Three, the sampling criteria was centred on biotech firms which 
reached the Initial Public Offering (IPO) stage. An IPO can provide an entrepreneurial 
firm with critical resources for its future expansion, and therefore IPO is regarded as 
one of the most important stages in the life of an entrepreneurial firm. Furthermore, 
IPO represents the first and most important ‘liquidity event’ (Daily et al., 2003). 
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Typically, the founders and early-stage investors use IPOs to appropriate a proportion 
of wealth associated with the venture (Bruton, Chahine and Filatotchev, 2009). In this 
analysis, the objective was to analyse and connect the process of knowledge creation 
(as represented by the data on the publications made by the biotech founders) with the 
appropriation of intellectual property rights through patents assignation. To this end, 
the IPO criteria served to further identify a successful stage within the R&D process. 
IPO documents also served as a source for biographical information, and were used to 
define the founders’ careers trajectories. 
 
Data collection and analysis 
For the purpose of the three studies, data was collected with a cross-sectional design 
format applied to the different contexts of analysis. A multiple-stage approach to the 
collection of the relevant information was employed.  
Essay One 
Systematic reviews are essential tools for summarising the extant literature accurately 
and reliably. The Cochrane library defines systematic reviews as the “attempts to 
collate all empirical evidence that fits pre-specified eligibility criteria to answer a 
specific research question” (Oxman and Guyatt, 1993; Lasserson, Thomas and 
Higgins, 2019), (p. XXIII) . The key element of systematic reviews, compared to 
narrative approaches is that “systematic methods are selected to minimise bias, thus 
providing reliable findings from which conclusions can be drawn and decisions made” 
(Liberati et al., 2009), (p.e2). The systematic approach has its origins in the medical 
sciences. In healthcare, scientific evidence plays a key role in informing decision-
making about the organisation and the delivery of health and social care, and 
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significant strides were made in the attempt to improve the quality of the review 
process by synthesising research in a systematic, transparent and reproducible manner 
(Tranfield and Mouchel, 2002; Wolf, Shea and Albanese, 2001; Tranfield, Denyer and 
Smart, 2003). In 2005, a group of 29 review authors, methodologists, clinicians, 
medical editors and consumers developed the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) statement  (Moher et al., 2009). 
PRISMA is composed of a 27-item checklist and a four-phase flow diagram used to 
enhance the selection of relevant studies and the reporting. PRISMA represents a way 
in which authors can ensure the transparent and complete reporting of systematic 
reviews and meta-analyses (Liberati et al., 2009). In contrast, in management research, 
the literature review process tends to be conducted mostly through narrative 
approaches. Tranfield, Denyer and Smart (2003) proposed applying specific principles 
of the systematic review methodology used in the medical sciences to management 
research. In the authors’ view, there was the need to counteract authorial biases by 
making explicit the values and assumptions underpinning a review. 
The guidelines suggested by  Tranfield, Denyer and Smart (2003) and the PRISMA 
diagram have been combined in Essay One. Furthermore, in order to get to a synthesis 
of these two approaches, the investigation was operationalised based on the work of 
(Di Maddaloni and Davis, 2017). Overall, my data collection strategy consisted of 
three levels, through a deductive approach representing the knowledge areas relevant 
for investigation. A first level (domain) was identified from the literature on 
university-industry relations, intended as the broad range of activities involving 
universities and industry within the economic system. A second level (phenomenon) 
was that of knowledge and technology transfer. A third and final level of analysis was 
that of the mechanisms of knowledge transfer, meaning the ways in which knowledge 
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moves across organisations. Overall, this top-down approach served the purpose of 
pinpointing the theoretical elements guiding my review. 
Relevant data was collected by employing a set of specific keywords, which had been 
previously tested and approved through discussion with senior academic supervisors 
and further developed into Boolean operators (Stage 1). In Stage 2 analysis, a set of 
selection criteria was rationalised, including the choice of databases (ISI, Web of 
Science), the year span (1980–2018) and the language of the articles (English). Next, 
a quality appraisal was conducted in order to further narrow down the publications 
reflecting high academic standards. The quality of publication data then was assessed 
through a two-step analysis (Stage 3). The first quality criteria were reflected by the 
number of yearly citations. Following  Crossan and Apaydin (2010) research, we 
identified high-impact publications which showed at least five citations per year, using 
2018 as the base year. Previous scholars have used the number of citations as an 
indicator of impact and performance, as well as an indicator of research excellence for 
an individual publication (Waltman and van Eck, 2013; Hicks et al., 2015). A further 
advantage of using citation-based indicators is that they are objective measures which 
reflect evaluation by subsequent researchers (Van Raan, 2004). The second quality 
criterion related to journal ranking. This was verified against CABS Journal Guide, 
the standard of reference for journals in the fields of innovation and business 
management. Stage 4 consisted of a content analysis of the publications (Mok, Shen 
and Yang, 2015). Titles and abstracts were included based on deductively formed 
themes with specific reference to the employed keywords. In this context, my attention 
was focused on identification and therefore included conceptual analysis of the 
knowledge transfer channels. I did not take in consideration articles which were 
focused exclusively on the technological aspects of knowledge from an empirical 
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point of view. The screening was conducted based on visual examination of titles, 
abstracts and texts. To avoid bias, two investigators performed a blind reading of the 
materials, and any disagreement or risk of bias was resolved through discussion with 
the supervisory team and I. Overall, the results of the selection process were included 
into the PRISMA chart, and the number of articles included and excluded at each stage 
of analysis was reported. 
Essay Two 
In Essays 2 and 3, I follow a bibliometric approach to data collection and analysis, 
involving the publications and patents authored/invented by the scientific founders of 
the biotech companies. Specifically in Essay Two, the database Beaurhurst contains 
key information on high-growth companies that have secured equity fundraising in 
UK, and this is accessed in order to retrieve the biographical information related to the 
founding scientists (full name, role, previous affiliation). Furthermore, in Essay Two 
a literature search was conducted in order to identify relevant publications made by 
the scientific founders. Two methods were employed for data retrieval, both focusing 
on the scientific production published before the year of company incorporation. The 
first data collection method (Method 1) identified the most relevant publications in 
terms of number of citations. As highlighted in Essay One, citations were employed 
as a measure for impact, and therefore the ten most cited articles were downloaded in 
order to capture the publications with the highest scientific relevance. A second 
research query (Method 2) was made by associating the founders’ identity with the 
information regarding the products in the company pipeline. Specifically, information 
such as therapy area, molecule type and mechanism of actions were included in the 
literature search. The objective was to identify the most relevant article per author 
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according to the company science. In other words, the intent was to identify the key 
publication containing the scientific discovery upon which the company was created. 
In this way, I tried to identify the link between the scientific production made before 
the company foundation and the applied science conducted thereafter, as highlighted 
by the company drugs pipeline. Overall, the two data collection strategies allowed me 
to include the most influential publications in the founders’ backgrounds (Method 1), 
as well as the research made in the areas that were then carried out within the founded 
enterprise and utilised as the basis for drug development (Method 2). 
Data analysis required the harmonisation of biographical information and 
disambiguation of author names to match author and as well as funder identity in 
publication data. Previous scholars highlighted that manual inspection to disambiguate 
authors can be very effective for small populations of scientists (D'Angelo, Giuffrida 
and Abramo, 2011), and therefore in Essay Two I took a manual approach to name 
disambiguation, which also involved a blind reading of the bibliometric material with 
the members of my supervisory team. This was required since several authors share 
the same name, but also one author might express his/her name in different ways. To 
this end, the Web of Science database provided a grouping option which allowed for 
the identification of specific authors and their publications. In Web of Science, author 
records are generated by a proprietary algorithm that identifies and weighs shared data 
elements such as author names, institution names, and citing and cited author 
relationships (source: Web of Science). 
Secondly, as the objective of the essay was to analyse the financial disclosure of 
acknowledgment sections, name disambiguation was required to correctly identify 
funders. The extraction, coding and interpretation of funding data was conducted 
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manually. Once the relevant funding information for a given publication was 
identified, the full name of the organisation was retrieved, and a thesaurus of the 
various names and acronyms of funding agencies was created. During a second stage, 
data names were cleansed and associated with country code and type, such as whether 
the funder was a non-profit organisation, a governmental body, charity, university or 
private financer. 
Finally, authors ‘affiliations were also coded and categorised. Affiliations were 
retrieved from the [C1] author address field in the Web of Science database. The [C1] 
field provides address information separately for each author, and lists more than one 
address per author where this occurs. Based on this information, the coding was 
undertaken semi-manually following (Hottenrott and Lawson, 2017). A search 
algorithm containing word elements such as “univ”, “hosp”, “ltd” was applied using 
Microsoft Excel. All entries were then checked, and organisation names were searched 
online to assign institution types (universities, hospitals or companies respectively). 
Essay Three 
Three main sources of data were considered in Essay Three: IPO documents, 
publications, and patents. IPO documents are considered a reliable source of 
information as they offer a unique opportunity to study the amount and type of 
voluntary disclosures to the capital market. IPO prospectuses are likely to be highly 
accurate because companies are liable for any misleading or inaccurate information 
(Daily et al., 2003). Under the regulations from the US Security and Exchange 
Commission (SEC), key information needs to be disclosed through certain documents 
within IPO prospectuses. Similarly, AIM Rule 26 obliges companies to disclose 
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information on the pre-IPO ownership structure, and such information must be made 
available to view free of charge. 
First, IPO prospectuses were downloaded from companies’ websites under the 
investor relations section, as required by the AIM Rule 26. In cases where it proved 
difficult to identify the bibliographic information of the founders, IPO material was 
integrated by searching for biographical information of the company Founders on 
crunchbase.com, as well as in the Beaurhurst dataset and companies’ websites. In 
order to characterise scientific founders’ career trajectories, two co-authors 
independently scanned, collected, and performed a blind reading of the biographical 
material. Based on this biographical information, three distinct career trajectories were 
defined: 
1. The industrial trajectory describes scientists who, subsequent to receiving 
training, have mainly spent their careers working in the drug industry, as well 
as scientists who have been employed by non-pharmaceutical firms. 
2. The academic trajectory includes scientists with stated academic positions or 
experience in research organisations. 
3. The mixed trajectory describes scientists who have worked in both industry 
and the academic research sector. 
Secondly, patent data in which the founders figured as ‘inventors’ was downloaded. 
For this purpose, patents were retrieved from ‘The Lens’ suite 
(https://www.lens.org/lens/), an integrated initiative by CAMBIA comprising patents 
registered within the European Patent Office’s (DOCDB) bibliographic data, the 
United States Patent Office (USPTO) database, data from the World Intellectual 
Property Organization (WIPO-PCT), and Australian patents. The main advantage of 
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using ‘The Lens’ suite is that inventor names are linked with social web directories 
(LinkedIn and ORCID), making it easy to further check on founders’ professional and 
scientific backgrounds. 
As a result, patents granted between 1980 and 2019 were included in the sample, but 
pending patent applications were excluded. Linked to patents, ‘The Lens’ suite also 
provides references to non-patent literature (NPL). NPL refers to the scientific 
literature cited by patent documents, and is commonly used as a proxy for knowledge 
flow between different organisations. Therefore, the NPL included in the patent 
documents by the scientific founders was also downloaded. 
Next, publication data authored by scientific founders was retrieved from ‘The Lens’ 
suite. A similar data collection strategy as in Essay One was applied. Specifically, 
articles published in peer-reviewed scientific journals between 1970 and 2019 were 
included. Meeting abstracts, commentaries and reviews were, however, discarded. 
Name disambiguation and data cleansing was conducted. The names of the scientists 
were carefully screened in order to match with those appearing in the patent 
documents and the publications. 
Based on patent and publication data, scientists were categorised based on their 
propensity towards publishing and patenting (Stokes, 2011; Hess and Rothaermel, 
2011; Baba, Shichijo and Sedita, 2009; Subramanian, Lim and Soh, 2013). 
Specifically, the average number of patents and publications per year was calculated 
based on the years during which each scientist had been active (i.e. the number of 
years between the first and the last publication/patent). The scientific production of 
each scientist was then compared to the mean number of patents/publications of the 
sample. Accordingly, scientific profiles were defined as follows: 
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1. Pasteur bridging scientists were those with above-average per-year patenting 
and publication records. 
2. Edison scientists were defined by above-average patenting records but below-
average annual publication records. 
3. Star non-patenting scientists were those with above-average yearly publication 
records but below-average annual patents. 
Lastly, patent assignees were categorised based on Eurostat’s project on Data 
Production Methods for Harmonised Patent Statistics   (Callaert et al., 2011). In 
particular, the assignee names containing business designations or not-for-profit entity 
names were checked. Assignees were coded as ‘CORP’ when the name contained a 
corporate designation. When the name of a university or research centre was found, 
patents were coded as ‘ACA’. Assignment to governmental bodies and public research 
institutes was coded as ‘PRO’. Unassigned patents were those assigned not to 
organisations but to individuals (Callaert et al., 2011).
 
 
CHAPTER 4: Contributions and Discussion 
 
In this chapter, I outline the general content and the contributions of the three essays 
which represent the main body of my doctoral work. The comprehensive description 
of the outcomes and discussion of results are described in detail in the three 
manuscripts, (Part II). 
The essays were written following the editorial requirements of highly ranked 
academic journals. Two essays were published after a rigorous peer review process. 
The third is currently under a second round of review. 
Main Contributions 
This research offers the opportunity to explore some important aspects of the 
innovation process in biotechnology, including the creation of basic knowledge and 
its appropriation for commercial use. 
These arguments have characterised the scientific debate on innovation for decades. 
Most previous analyses focused on the transfer of knowledge and technology from 
university to industry. The literature on scientific and technical human capital 
investigates the dynamics of academic communities and the engagement of firms in 
the norms of science. Entrepreneurial perspectives are typically used to analyse the 
behaviour of academic entrepreneurs, technology transfer offices and spin-offs, as 
well as the changing roles that universities play in the economy. To our knowledge 
this is the first attempt to bring these perspectives together. As a result, this research 
is genuinely multidisciplinary. The innovativation that characterises this doctoral 
research is the focus on biotechnology founders and the role they play as conduits for 
 
 
the transformation of knowledge into practice. My works traces back to the origins of 
innovation, while maintaining an external look at the ‘transformation’, rather than the 
‘transfer’, of knowledge embedded in such individuals. 
A first contribution stems from the systematic revision of the literature (Essay One). 
Here the variety and the relation between knowledge transfer mechanisms was 
investigated. Knowledge transfer mechanisms were characterised by different degrees 
of formalisation, relational involvement, direction and time. Determinants of these 
mechanisms were found in the characteristics of knowledge, individuals, organisations 
and disciplines. As a result, a new taxonomy was framed which distinguishes between 
channels and processes of knowledge transfer. Channels are linear configurations 
which allow the transfer of codifiable content, such as publications and patents. 
Processes are defined as multidimensional spaces that reflect different degrees of 
relational involvement, such as the entrepreneurial activity of scientists. 
Based on this taxonomy, the second essay focuses on publication by biotech founders. 
The objective was to investigate the nature of the funding given to basic knowledge 
embedded in these scientific entrepreneurs. Rather than focusing on research budgets 
top-down, the paper develops a bottom-up approach based on the acknowledgment 
sections of key publications by biotech founders. As a result, the study highlights the 
contributions given to science that have transformed into business. As a result, the 
paper evidences that public institutions finance a substantial part of the knowledge 
published by the scientific founders of biotechnology enterprises. 
The third essay investigates the direction given to the knowledge produced by biotech 
founders and financed by public institutions. The observation is made on the patents, 
the channels through which valuable inventions are protected and rights to use are 
 
 
assigned. The work makes multiple contributions. First, it adds further elements that 
characterise the career trajectories of scientists who found biotechnology companies. 
It highlights that scientific human capital behind biotech companies is heterogeneous, 
and this demonstrates the value of adopting a broader view, rather than being restricted 
to academic publishing and patenting. Second, the analysis of patent assignation 
provides important elements in understanding the patent ownership landscape in 
Europe. Previous analyses of academic patenting claim the presence of private 
ownership model in Europe and associated this with factors such as a professor’s 
privilege with regard to different institutional schemes. This work uncovers an 
important element, that in the most part corporate ownership can be explained through 
the assignation of IPR to start-up companies. Third, the results of my regression model 
show that academics have stronger incentives than scientists with careers spent in the 
industry, to capitalise on the discoveries made by assigning the patent property to their 
own start-ups. By contrast, the study finds that corporate scientists have stronger links 
with their employers as they show stronger likelihood of assigning to them the 
inventions they patent.  
Overall, based on the combined outcomes of the three essays, this thesis shows that 
public institutions back up the creation of valuable inventions by financing the 
knowledge produced by academic scientists. Academics capitalise on their experience 
at university by assigning the majority of patents to their own start-ups. In this light, 
the papers presented here support the argument that the risks that characterise 
knowledge creation and the rewards connected with the appropriation of economic 




  Title Status Research Questions Objective Main Outcomes Contribution 
Essay One Channels and processes 
of knowledge transfer: 
how does knowledge 
move between 





1. What determines the 
movement of knowledge 
between university and 
industry?  
2. What are the 
characteristics of the 
transport mechanism? 
To gain a better 
understanding of 
academia–industry 
interactions and to 
explore the conduits of 
knowledge transfer. 
Determinants for the adoption of 
knowledge transfer mechanisms 
were: knowledge, individuals, 
organisations and disciplines. 
Knowledge transfer mechanisms can 
be classified based on degrees of 
formalisation, relational 
involvement, direction and time. 
Overall, knowledge content, 
embedded in individuals or 
processes within organisations, is the 
main component which drives the 
adoption of knowledge transfer 
mechanisms. 
A new taxonomy was 
proposed. I define 'channels' 
as media through which 
encoded knowledge is 
transferred uni-directionally. 
'Processes' are social 
configurations in which coded 
and encoded knowledge is 
shared (multi-directional) 
with an increasing level of 
relational involvement. 




bibliometric analysis of 





1. What is the nature of 
the financial support 
acknowledged in the 
publications by biotech 
founders? 
2. What is the 




3. To what extent does 
funded research have a 
higher impact in terms of 
article citations? 
To analyse the nature and 
scope of the financial 
contribution 
acknowledged in 
publications by scientists 




The support from public institutions 
was reported by the majority of 
publications. Most scientists were 
affiliate with public institutions. 
Public institutions play a 
major role in the financing of 
basic knowledge produced by 
academic scientists who are 






Table 2: Main results and contributions by the three essays
Essay Three R versus D, from 
knowledge creation to 
value appropriation: 
ownership of patents 
filed by European 
biotechnology founders. 
Under review- 
second round by 
Technovation 
1. What is the scientific 
human capital upon 
which European 
biotechnology firms are 
created? 
2. To what extent is the 
assignation of intellectual 
property rights sensitive 
to:  
2.1. the inventor’s 
professional career; 




To analyse the career 
trajectories and research 
backgrounds of biotech 
founders and by what 
means these affect the 
assignation of intellectual 
property rights and 
thereby the appropriation 
of knowledge. 
Biotech founders show 
heterogeneous career backgrounds 
across academia and industry. 
Patents are assigned, in the main, to 
their own start-ups. Academic 
founders show stronger incentives to 
transfer their inventions to the start-
ups than industrial scientists. 
Industrial scientists have stronger 
ties with their employer than 
academics with university.  
Biotech founders capitalise on 
their research and professional 
backgrounds by assigning the 
IPRs of their inventions to 




As with all forms of empirical research, this work is recognised to have some 
limitations. Overall, the critical elements that should be considered when interpreting 
the results of this research concern the methodology applied for the identification of 
scientists involved in company’ creation and the relative publications and patents. 
Certainly, the bibliometric approach adopted in the studies represents a strength of this 
work, for its ability to track the development of individual innovators and the 
transformation of their knowledge into products. As I have largely illustrated in the 
previous chapters, no attempts were made by scholars to investigate the innovation 
process starting from its final product. At the same time, due to the lack of previous 
evidence in employing a similar approach, the approach itself is also a study limitation. 
Several efforts were required to standardise data collection procedures and to retrieve 
the relevant information without compromising the validity of the results. 
In this context, a specific limitation concerns the process of identifying the scientific 
founders of biotech companies. Biographies and information on their accounts were 
not always available from the companies’ websites or from institutional sources and 
online databases. This was particularly true when the scientists had multiple 
appointments with public and private organisations (mixed career scientists). 
Therefore, to avoid errors, data on biotech founders was retrieved from different 
sources (see chapter 3, p.41), and then triangulated. Also, more than one researcher 
was involved in the double blind reading of the retrieved material and disagreements 
among the team members were solved through discussion. Overall, a conservative 
approach was followed, in that when the information was not sufficient to correctly 
characterise the identity of the founders, these were dropped from the analysis. Once 
founders’ identities were clarified and included, a second limitation was the process 
 
 
of name disambiguation to associate publications and patents with each of the 
founders. To this end, I relied on data sources, disposing of automised systems for 
author disambiguation, such as ‘Web of Science’ and ‘Lens’. Also, the triangulation 
of different data sources allowed control for bias.  
In conclusion, despite the subjectivity of the author and the supervisors being reduced 
to a minimum, the observed sample of biotech companies and founders suffers from 
the standardised procedures and exclusion criteria adopted to avoid selection bias. For 
example, the choice of including drug originating companies certainly allows for the 
observation of companies started with the sole purpose of developing ideas and 
technologies into products. At the same time, the decision made in the Essay Three to 
focus on biotech companies that reached IPO underlines the relevance of this choice 
for the purpose of tracking the genesis of ideas and their transformation into drug 
compounds. These choices were also consistent with the need to create standardised 
procedures to discover the origins of innovations. By contrast, through this approach 
biotech companies that failed or did not reach a successful stage of venture financing 
as well as those licensing out their inventions to other enterprises, were left out of the 
analyses. Overall, in the light of these limitations, future researchers may consider 
extending this thesis and drive more empirical investigations on the topic to strengthen 
the validity of the bottom-up approach for analysing innovations as delineated in this 
dissertation book. I propose some lines of research in the next paragraph. 
 
Future Research 
Overall, this research aims to contribute to the debate of how to achieve a fair 
distribution of risks and rewards between actors at different stages of the innovation 
process. Previous scholars, such as Lazonick and Mazzucato (2013), have made 
 
 
substantial contributions to this field by highlighting the ‘risk-reward nexus’ that seeks 
to analyse the ways in which risks and rewards can be aligned with contributors to the 
innovation process. In line with the contributions by these scholars, my work 
highlights the collective aspect of knowledge creation and tracks the contribution of 
actors of different kinds to the innovation process in biotechnology. Future research 
in this field should pay attention to factors that have limited the analysis performed 
here, and should extend the purposes of the investigation to aspects that my research 
has not fully addressed. For example, scholars may find interesting the application of 
my bottom-up approach to track the genesis of innovations in fields other than 
biotechnology. Authors may perform qualitative research on biotech founders to 
investigate further the extent to which scientists seek to capitalise on their academic 
research by starting biotech companies. Qualitative research would be also useful for 
the purpose of confirm the validity of bibliometric data associated with founders’ 
identities, and could provide a standardised procedure that can be replicated in 
different fields. Furthermore, another aspect I deem relevant of attention by future 
scholars is the study of the collaborative efforts of scientific founders. Understanding 
to what extent authors affiliated to the same institution face incentives to bypass formal 
institutional channels, such as TTOs, could be an interesting perspective from which 
to look at the network of individual relations that characterise the transfer of 
knowledge to the private sector. Lastly, the approach undertaken in this thesis opens 
the way for future analyses to clarify and measure the risks undertaken by actors 
positioned at the early stages of the R&D process. This, perhaps, is the major challenge 
for future research developments, as the quantification and assessment of risks is made 
difficult by the inherent uncertain characteristics of innovation. However, a bottom-
up approach to the analysis of risks undertaken by organisations that finance single 
 
 
research initiatives and scientists may be an alternative strategy to the top-down 
analysis of research budgets. 
In conclusion, this book advocates a wide and dynamic approach to how value is 
created. Contributions in this field are relevant for advancing evidence needed for 
price negotiations between manufacturers and public payers. Therefore, my research 
calls for more efforts towards understanding and supporting equitable and accessible 
ways to provide innovation. 
 
Policy Reflections 
By highlighting the dynamics behind the division of labour in the biopharmaceutical 
industry, this thesis provides new evidence that may influence the policy debate on 
innovation. Based on the results of my essays, I claim that the debate on the 
distribution of risks and rewards between the actors on the innovation process should 
recognize not only the roles of public and private organizations, but also that of key 
individual actors, such as the entrepreneurial scientists.   
My reflections are inspired by those of previous scholars such as Mazzucato and 
Lazonick who pointed out that the collective, cumulative and uncertain aspects of the 
innovation process make possible a disconnect between who bears the risks and who 
gets the returns from the investments in R&D (Lazonick and Mazzucato, 2013). In the 
entrepreneurial theories of the State by Mazzucato, the public sector co-creates, and 
not just fixes, the market (Mazzucato, 2011). Public institutions shape the innovation 
process without limiting their role to the upstream investments in R&D, but actively 
contributing to the success of innovating companies and products such as those in the 
tech and pharmaceutical industries. By acknowledging the State plays a key role as 
 
 
risk-taker, the entrepreneurial theories justify the reap of a share of the financial 
rewards and, thus, the use of instruments to appropriate returns. This approach is 
opposite to the traditional view of market failures in which the State fixes the market 
dysfunctions and gets the returns of a societal nature, such as job creation, economic 
growth and positive fiscal impact (Laplane and Mazzucato, 2020).  
By maintaining the view of the Entrepreneurial State, my essays demonstrate that a 
way in which the public sector co-creates, and shapes biotechnological innovation 
outputs is through investments in scientific and human capital of key bridging 
scientists. My research points out that public institutions bear a high risk which is that 
of investing in the training, and formation of scientists and operating as the embryonal 
context in which the knowledge is created. Therefore, by pointing out the dynamics 
behind the movement of scientists along the innovation process, my works point out 
the need to combine the individual with the organizational levels when designing 
policies to align the risk-reward nexus.  
In my research I show that scientists position themselves along the innovation process 
so as to appropriate and maximise a portion of the value they contribute to create 
through their discoveries. On the one side, in Essay Two, I point out that a great portion 
of their discoveries are co-created by universities and public institutions that also 
support research projects financially. On the other side, in Essay Three, I show that 
university scientists have strong propensities to maximise their rewards by assigning 
the intellectual property of patents to the biotech companies they start their own. In 
sum, my research highlights that the ‘Entrepreneurial State’ is made by 
‘Entrepreneurial Universities’ which are in turn made by ‘Entrepreneurial Scientists’. 
Therefore, in the logic that aims to assess the risks and the rewards of the public and 
 
 
private organizations in the innovation process, it is necessary to look also at the risk-
reward nexus that involves each of these levels.  
Adopting an individual perspective can be relevant for the design of appropriate fixes 
to the innovation process. From a macro perspective, Mazzucato propose several 
instruments to ensure the State with the possibility to get a fair share of rewards, the 
so-called ‘socialization of rewards” (Laplane and Mazzucato, 2020). Examples of 
instruments are profit sharing via royalties on sales or equity, or conditionality 
instruments such as the pricing of final goods as well as the use of mission-oriented 
public finance. One field of application is the control over drug pricing. In the US, 
some authors have discussed the use of “march-in-rights” as provisioned by the Bayh-
Dole Act, and never used by governments (Arno and Davis, 2000; Alperovitz and 
Daly, 2009). By contrast, other scholars have pointed out that using control pricing 
would discourage private investment to bring early discoveries to the marketplace 
(Thomas, 2016; Treasure, 2016).  
In the European context, finding appropriate policy measures to adopt is made harder 
by the fact that legal prescriptions in the kind of the Bayh-Dole Act are not adopted 
uniformly and the presence of “professor privilege” regulations still characterises 
many of the national patent contexts. However, the role of public authorities in the 
negotiation of prices and access to medicines, under the “value-based” pricing 
approach, constitute an important space to implement a risk-reward narrative in the 
European landscape. From the perspective of health systems facing budgetary 
concerns and the contemporary soring price of some pharmaceuticals, it is important 
to re-establish a symbiotic relation between the risk takers organizations and the 
individuals who appropriate the economic rewards.  
 
 
Bibliometric data employed in this thesis offers a unique lens to highlight a small, yet 
relevant aspect of this phenomenon, through the explanatory potential of micro-level 
analysis conducted on individual innovators. Therefore, enhancing the availability of 
financial information behind knowledge creation, such as the disclosure of financial 
contributions in publications and patents documents, is key for the future development 
of models for risk assessment at individual levels. A better understanding of these 
dynamics may help bring new evidence that may influence the negotiation of fair 
prices and contribute to the debate on how risks and rewards can be fairly distributed 
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Abstract:  
The role of knowledge and technology transfer between academia and the industry has 
received increasing attention in the analysis of innovation. This paper aims to explore 
the scientific literature concerning knowledge transport mechanisms and describe how 
the topic was organized by previous studies and terminologies applied. A systematic 
review was conducted in which the content of recent contributions best fitting these 
intensions was analysed. The characteristics of knowledge, individuals, organizations 
and disciplines were found to be the main determinants in the adoption of transfer 
mechanisms. These were classified in terms of formalization, relational involvement, 
direction and time. On the revealed multi-dimensionality of knowledge transfer and 
complementarity between transfer activities we framed a new taxonomy 
distinguishing between channels and processes. Future research may deepen these 
factors, such as the economic aspects driving the adoption of transfer mechanisms 
informing decisions on the funding of innovation. 




Essay Two – Title: Public-private contribution to biopharmaceutical 
discoveries:  a bibliometric analysis of biomedical research in UK. 
 
Authors: Gianluca Fabiano, Andrea Marcellusi, Giampiero Favato 
Affiliation: Institute for Leadership and Management in Health, Kingston University 
London, London, UK. 
Published in: Scientometrics 124, 153–168 (2020). https://doi.org/10.1007/s11192-
020-03429-1 
Journal ranking: 2 stars ABS, Impact Factor: 2.867 (2019) 
Abstract: 
Basic research creates new knowledge that fuels technological advances. However, 
budgetary concerns and escalating R&D prices are challenging organizations to show 
returns from investments in scientific research. Few attempts are made to analyse 
research that leads to pharmaceutical innovation. In particular, the financial 
contribution of public and private organizations to the riskiest stage of biomedical 
discovery has remained unclear and partially unexplored. 
This study is a first attempt to shed light on the financial support to basic research by 
public and private sectors using publications data. We conducted an exploratory 
analysis of funding acknowledgments (FA) on publications authored by the founding 
scientists of 91 'drug originator' companies in United Kingdom. The nature and 
distribution of the support acknowledged to the research conducted before the 
company creation was analysed and the impact of publications and type of support 
were statistically tested.   
We found the majority of publications acknowledged public institutions, whereas, 
commercial organisations were likely to support those with privately affiliated 
authors. Based on these findings, we discussed the need to foster collaborative 
 
 
research and to set adequate incentives for shared risks and benefits from investments 
in knowledge creation.  
Keywords: basic research, drug discovery, innovation, funding acknowledgment 
 
Essay Three – Title: R versus D, from knowledge creation to value 
appropriation: Ownership of patents filed by European biotechnology 
founders 
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Abstract: 
Biotechnology firms are often created on the premise of commercializing the results 
of research carried out by scientists with heterogeneous careers and research 
trajectories. Patents filed by company founders provide accessible information on the 
appropriation of knowledge through the assignment of intellectual property rights 
(IPR). 
In this study, we developed a novel database of patents and publications by the 
founders of European drug-originating biotech companies that reached IPO between 
2013 and 2018. The founders’ scientific human capital was analysed. Moreover, we 
developed a regression model to estimate whether the founders’ career trajectories, 
previous publications and patent characteristics affected the likelihood of the use of a 
university versus an industry patent ownership model. 
 
 
Our findings suggest that founders’ scientific human capital influences the way 
knowledge is captured for economic use. Compared to patents filed by industrial 
inventors, those filed by academics are more likely to be assigned to the inventor’s 
own start-up company or to universities and public research organizations (PROs) than 
to be appropriated by private organizations other than the one founded by the inventor. 
Patent data, when not restricted to university members, provide a very comprehensive 
picture of the knowledge transfer activities. This lens encourages fundamental 
questions about biopharmaceutical innovation regarding issues such as whether risks 
and returns are appropriately shared between actors in the public and private sectors. 
Keywords: patent ownership; scientific founders; knowledge technology transfer; 
European biotechnology 
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"Professor James Lorens is the co-founder of BerGenBio, serves as the company’s Senior Scientific 
Advisor and is also a Professor at the Department of Biomedicine at the University of Bergen.  On 
completing his postdoctoral research studies at Stanford University he joined Rigel Inc., a San Francisco 
based biotechnology company, as a founding scientist and research director. Prof. Lorens has managed 
several large scientific collaborations in cancer research and development with major pharmaceutical and 
biotechnology companies”. 
 
"Prof. Riedemann received his medical training at Freiburg, Germany, and Stanford University, USA. He 
performed basic science research at The University of Michigan in the field of complement immunology 
and inflammation for several years and then completed his board certification in General Surgery at 
Hannover Medical School, where he still holds a Professorship in Experimental Surgery.". 
Industrial trajectory 
"Dr Love was a senior scientist at Ciba Geigy/Novartis focused on novel drug delivery technologies and 
involved in the development of the world’s leading eye-care pharmaceutical, Visudyne. In 1997, Dr Love 
founded Destiny Pharma and he is the co-inventor of the XF drug platform. Dr Love was a founding 
member of the BEAM Alliance, an EU SME group focused on promoting antimicrobial drug development 
[...]" - Ph.D. in Drug Delivery University of Wales. 
 
"After gaining a PhD in pharmacology from the University of Dijon, Philippe Genne began his scientific 
career as a project leader at Debiopharm where he oversaw a clinical development program related to 
multi-drug resistance inhibitors. He also worked as a research associate at Glaxo-Welcome." -  PhD in 
pharmacology from the University of Dijon. 
 
Mixed trajectory 
"Pascale Fouqueray joined Merck KGaA in 2000 from Paris VII University, where she was Assistant 
Professor of physiology. At Merck KGaA, Dr. Fouqueray's activities were centered on metabolism, with a 
particular focus on diabetes and obesity but also including lipids and uric acid metabolism. Dr. Fouqueray 
was responsible for the clinical development of compounds for the treatment of diabetes and gout disease, 
working on strategies to define and reach proof-of- concept and investigate mechanisms of action"- PhD 
from the University of Paris XI. 
“Daniel Obrecht, Ph.D., spent 11 years at the Central Research Laboratories of Roche Basel. In his 
previous position he was Head of the Combinatorial Chemistry Group. Dr. Daniel Obrecht obtained his 
Ph.D. in Chemistry from the University of Zurich in 1985 under the supervision of Prof. H. Heimgartner, 




 Table 2: Correlation matri



















Inventor Professional Trajectory Pearson Correlation 1 0.017 -0.053 .133** -0.062 -0.060 -.113** -0.031 -.092** 
  Sig. (2-tailed)   0.597 0.127 0.000 0.059 0.069 0.001 0.345 0.005 
No. previous patents Pearson Correlation 0.017 1 .093** 0.036 .121** -0.024 .132** .217** 0.052 
  Sig. (2-tailed) 0.597   0.007 0.293 0.000 0.465 0.000 0.000 0.114 
No. previous publications Pearson Correlation -0.053 .093** 1 .136** -0.010 -.095** .094** -0.022 -0.007 
  Sig. (2-tailed) 0.127 0.007   0.000 0.781 0.006 0.006 0.525 0.850 
Applicability Pearson Correlation .133** 0.036 .136** 1 0.024 -0.035 -.079* -0.040 -0.023 
  Sig. (2-tailed) 0.000 0.293 0.000   0.491 0.310 0.022 0.250 0.506 
Backward citations Pearson Correlation -0.062 .121** -0.010 0.024 1 .287** 0.048 0.039 .692** 
  Sig. (2-tailed) 0.059 0.000 0.781 0.491   0.000 0.140 0.232 0.000 
Forward citations Pearson Correlation -0.060 -0.024 -.095** -0.035 .287** 1 -0.047 -0.032 .287** 
  Sig. (2-tailed) 0.069 0.465 0.006 0.310 0.000   0.152 0.327 0.000 
No. assignees Pearson Correlation -.113** .132** .094** -.079* 0.048 -0.047 1 .127** 0.030 
  Sig. (2-tailed) 0.001 0.000 0.006 0.022 0.140 0.152   0.000 0.361 
No. inventors Pearson Correlation -0.031 .217** -0.022 -0.040 0.039 -0.032 .127** 1 0.047 
  Sig. (2-tailed) 0.345 0.000 0.525 0.250 0.232 0.327 0.000   0.151 
NPL Citations Pearson Correlation -.092** 0.052 -0.007 -0.023 .692** .287** 0.030 0.047 1 
  Sig. (2-tailed) 0.005 0.114 0.850 0.506 0.000 0.000 0.361 0.151   
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